DOI: 10.1055/s-00000020

Geburtshilfe und Frauenheilkunde

References

Vergote I et al.
Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.
2009. (1879-0852 [Electronic])

Download Bibliographical Data

Access: